These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15165506)

  • 1. An interview with Doriano Fabbro, Ph.D., Novartis Biomedical Research Institute. Interviewed by Vicki Glaser.
    Fabbro D
    Assay Drug Dev Technol; 2004 Apr; 2(2):109-14. PubMed ID: 15165506
    [No Abstract]   [Full Text] [Related]  

  • 2. [Molecular targeted therapy for malignant brain tumors].
    Okamura T; Kurisu K
    Nihon Rinsho; 2005 Sep; 63 Suppl 9():520-6. PubMed ID: 16201575
    [No Abstract]   [Full Text] [Related]  

  • 3. Patent news.
    Steele P; Sparrowhawk M
    IDrugs; 2003 Dec; 6(12):1195-7. PubMed ID: 14712831
    [No Abstract]   [Full Text] [Related]  

  • 4. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular targeting in the treatment of lung cancer--toward the development of individualized treatment].
    Sone S; Kakiuchi S; Yano S
    Nihon Naika Gakkai Zasshi; 2004 Sep; 93(9):1963-70. PubMed ID: 15515691
    [No Abstract]   [Full Text] [Related]  

  • 6. An interview with Steven M. Watkins, Ph.D., president and chief scientific officer, Lipomics Technologies, Inc. Interview by Vicki Glaser.
    Watkins SM
    Assay Drug Dev Technol; 2004 Aug; 2(4):339-43. PubMed ID: 15357914
    [No Abstract]   [Full Text] [Related]  

  • 7. An interview with Paul England, Ph.D., ProXara Biotechnology, Ltd. Interviewed by Vicki Glaser.
    England P
    Assay Drug Dev Technol; 2004 Apr; 2(2):115-20. PubMed ID: 15165507
    [No Abstract]   [Full Text] [Related]  

  • 8. An interview with Ronald M. Evans, Ph.D. Investigator, the Salk Institute for Biological Studies.
    Evans RM
    Assay Drug Dev Technol; 2003 Dec; 1(6):749-54. PubMed ID: 15090221
    [No Abstract]   [Full Text] [Related]  

  • 9. Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells.
    Desplat V; Lagarde V; Belloc F; Chollet C; Leguay T; Pasquet JM; Praloran V; Mahon FX
    Cytometry A; 2004 Nov; 62(1):35-45. PubMed ID: 15468123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors.
    Casali PG; Bertulli R; Fumagalli E; Coco P; Grosso F; Stacchiotti S
    J Chemother; 2004 Nov; 16 Suppl 4():55-8. PubMed ID: 15688611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors.
    Eisenberg BL
    Oncology (Williston Park); 2003 Nov; 17(11):1615-20; discussion 1620, 1623, 1626 passim. PubMed ID: 14682111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gold standard or wrong standard?
    Oldham R; Dillman R
    Cancer Biother Radiopharm; 2004 Jun; 19(3):271-2. PubMed ID: 15285873
    [No Abstract]   [Full Text] [Related]  

  • 13. An interview with Peter J. Coassin. Interview by Vicki Glaser.
    Coassin PJ
    Assay Drug Dev Technol; 2005 Apr; 3(2):125-31. PubMed ID: 15871687
    [No Abstract]   [Full Text] [Related]  

  • 14. "To patent or not to patent? the case of Novartis' cancer drug Glivec in India".
    Gabble R; Kohler JC
    Global Health; 2014 Jan; 10():3. PubMed ID: 24393270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate acts in metastatic or unresectable gastrointestinal stromal tumor by targeting KIT receptors--a review.
    Sawaki A; Yamao K
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S44-9. PubMed ID: 15309514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interview with Marc Ferrer, Ph.D.. Interview by Vicki Glaser.
    Ferrer M
    Assay Drug Dev Technol; 2010 Jun; 8(3):263-7. PubMed ID: 20589994
    [No Abstract]   [Full Text] [Related]  

  • 17. An Interview with Jesús "Tito" González, Ph.D., Senior Director, Biology, Vertex Pharmaceuticals, San Diego, CA: interviewed by Vicki Glaser.
    Gonzalez J
    Assay Drug Dev Technol; 2008 Apr; 6(2):143-7. PubMed ID: 18471072
    [No Abstract]   [Full Text] [Related]  

  • 18. Repurposing medicinal compounds for blood cancer treatment.
    McCabe B; Liberante F; Mills KI
    Ann Hematol; 2015 Aug; 94(8):1267-76. PubMed ID: 26048243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate.
    Waller CF
    Recent Results Cancer Res; 2010; 184():3-20. PubMed ID: 20072827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.